Daewoong readies wrinkle injection for China Phase III



South Korea-based Daewoong Pharmaceutical is reportedly preparing to enter the final Phase III stage of clinical testing in China for its botulinum toxin product Nabota. According to the source, Daewoong on March 6 secured National Medical Products Administration (NMPA) approval to change Nabota’s manufacturing site to a commercial-scale facility in order to supply the Phase III trials, which means the study is expected to get under way during the second half of 2019. Daewoong’s second facility has a capacity of 4.5 million vials per year.

Nabota, used as a cosmetic therapy, has been commercialized in South Korea since 2014, won approval in the U.S. as a generic version of Allergan’s Botox in January this year, and is also under development for the European market. Daewoong won its first clinical trial approval for the drug in China in January 2018, as reported by GBI.


Reference:

Related news
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (600196.SH) announced that its subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd, has entered into a licensing agreement with U.S.-headquartered Revance Therapeutics Inc., (NASDAQ:RVNC) related to the latter’s daxibotulinumtoxin A for injection (RT002).
Ireland-headquartered Allergan plc (NYSE: AGN) is set to establish its first Medical Aesthetics Innovation Center in Chengdu, China, according to a press release.
South Korea-based Daewoong Pharmaceutical is progressing its botulinum toxin (BTX) type A product Nabota towards the China market, with plans to initiate a Phase III clinical study imminently after receipt of China Food and Drug Administration (CFDA) clinical trial approval, according to South Korean media.
The China Food and Drug Administration (CFDA) has released a warning on its website regarding Botulinum toxin type A for injection.
  • 1464923190585
  • China
  • Drug
China-based Bloomage BioTechnology Corporation Ltd, (HK: 963) has announced a collaboration with South Korea's Medytox Inc., (KS:086900) to establish a joint venture (JV) focused on developing and co-promoting Botulinum toxin type A injection in China.
  • 1438156883983
  • China
  • Deals
Recent news
Alfonso Ramírez Cuéllar, president of the Budget Commission in Mexico’s House of Representatives, urged the Ministry of Finance and Public Credit (SHCP) to disclose the names of 10 pharmaceutical companies that have received contracts for 80% of the consolidated drug purchases during previous administrations.
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last month approved Switzerland-based Roche’s hemophilia drug Hemlibra (emicizumab), as GBI analysis found.
France-based Sanofi-Aventis saw its diabetes drug Soliqua (insulin glargine + lixisenatide) obtain registration from Colombia’s National Food and Drug Surveillance Institute (INVIMA), according to GBI analysis.
According to GBI analysis, Ecuador’s National Agency for Health Regulation, Control and Surveillance (ARCSA) last month granted registration to Switzerland-based Ferring’s oral anti-inflammatory Cortiment (budesonide).
Switzerland-based giant Novartis AG has officially launched its Ultibro (indacaterol glycopyrronium bromide, powder for inhalation, hard capsules) and Seebri (glycopyrronium bromide, powder for inhalation, hard capsules) chronic obstructive pulmonary disease (COPD) maintenance therapies into the Chinese market.
  • 1552880244053
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the receipt of clinical trial approvals in China, Spain, and Poland for its histone deacetylase (HDAC) inhibitor abexinostat in combination with pazopanib for patients with renal cell carcinoma (RCC).
  • 1552879902162
  • China
  • Drug
China-based vaccines specialist CanSino Biotechnology Inc., is moving to hold an initial public offering (IPO) of 5,725,200 H shares to the Hong Kong Stock Exchange (HKSE) Main Board from March 28, 2019 alongside another 51,523,400 H shares to the global market, with the price range currently at HKD 21 to HKD 22 per share.
Analytics Snapshot


Understand market developments and maintain your competitive advantage.